This analysis examines the market position and future outlook for Amgen. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis and assessment of financial performance, with US, rest of world and global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information
Reasons to Purchase:
- Evaluate the threat of biogenerics to Amgen's US sales
- Benchmark Amgen's performance against key rivals in the ethical pharmaceutical and biotechnology sectors
- Evaluate Amgen's growth drivers that will contribute to the company's forecast growth through to 2010
